Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) generates frequent news related to its development of immuno-pharma therapeutics, particularly its flagship product candidate Ampligen (rintatolimod). Company announcements emphasize research and development in cancers, viral diseases, immune-deficiency disorders, and cancers with unmet medical needs, as well as updates on its intellectual property portfolio and corporate actions.
News coverage for AIM ImmunoTech often focuses on clinical and scientific milestones. Recent communications describe progress in the DURIPANC clinical program, where Ampligen is evaluated in combination with AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer, and presentations of data from a completed Phase 2 study in advanced recurrent ovarian cancer combining Ampligen with cisplatin and Merck’s Keytruda (pembrolizumab). The company also highlights publications in peer-reviewed journals and abstracts accepted at major scientific meetings such as the Society for Immunotherapy of Cancer (SITC).
Another recurring theme in AIM’s news is the expansion of its intellectual property. The company has announced a European patent covering compositions of its proprietary dsRNAs, including Ampligen, for treating Long COVID, and a patent in Japan for using Ampligen with checkpoint inhibitors for cancer treatment. These updates are presented as part of AIM’s strategy to strengthen protection around Ampligen in oncology and post‑COVID indications.
Investors following AIM ImmunoTech’s news will also see items on financial and corporate developments, including stock dividends, participation in investor conferences, public offerings of common stock and warrants, and financing agreements such as a promissory note with an institutional investor. Regular news releases on quarterly financial results, capital-raising transactions, and shareholder meetings provide additional context on the company’s operations and governance.
This news page aggregates such announcements so readers can review AIM ImmunoTech’s clinical updates, patent developments, financing activities, and corporate communications in one place.
AIM ImmunoTech (NYSE American: AIM) has completed its previously announced public offering, raising $8.0 million in gross proceeds. The offering consisted of 2,000,000 shares of common stock (or pre-funded warrants) along with Class E and Class F warrants at a combined price of $4.00 per share.
The offering included Class E warrants expiring in 5 years and Class F warrants expiring in 18 months, both with an exercise price of $4.00 per share. Maxim Group LLC served as the sole placement agent for this transaction, which was conducted under an effective S-1 registration statement.
AIM ImmunoTech (NYSE American: AIM) has announced the pricing of a $8.0 million public offering. The offering consists of 2,000,000 shares of common stock (or pre-funded warrants), along with Class E and Class F warrants, priced at $4.00 per share.
The offering includes Class E warrants expiring in 5 years and Class F warrants expiring in 18 months, both with a $4.00 exercise price. Maxim Group LLC is serving as the sole placement agent, with the offering expected to close around July 30, 2025.
AIM ImmunoTech (NYSE American: AIM) has reported positive mid-year data from its Phase 2 DURIPANC study, evaluating the combination of Ampligen® (rintatolimod) with AstraZeneca's Imfinzi® (durvalumab) for treating metastatic pancreatic cancer patients.
The study, conducted in collaboration with AstraZeneca and Erasmus Medical Center, has enrolled 14 out of 25 planned subjects. Key findings include: no significant toxicity, approximately 21% of patients showing PFS >6 months, and 64% of eligible patients achieving OS >6 months. The trial builds on previous successful results of Ampligen as a monotherapy in over 50 pancreatic cancer patients.
AIM has secured intellectual property protection through a U.S. patent extending to 2039 and orphan drug designations in both the U.S. and EU for Ampligen in pancreatic cancer treatment.
AIM ImmunoTech (NYSE American: AIM) announced a presentation at the U.S.-Poland Science and Technology Symposium 2025 featuring Dr. Pawel Kalinski's discussion on the company's drug Ampligen. The presentation, held from June 17-20, 2025, focused on the potential of private-public partnerships in developing oncology treatments.
Dr. Kalinski, a senior investigator for multiple Ampligen oncology studies, highlighted opportunities for expansion in the United States and Eastern European countries through initiatives like the Translational Research Cancer Centers Consortium. CEO Thomas K. Equels will pursue potential clinical partnerships and licensing agreements in Europe, particularly in Poland, at the upcoming Marie Sklodowska-Curie Symposia in September 2025.